ClinicalTrials.gg
CompletedNCT03551171Updated Jan 24, 2019

The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer

A Phase 1 interventional study of ZL-2306 (niraparib) in Ovarian Cancer, sponsored by Zai Lab (Shanghai) Co., Ltd.. Completed at 6 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-24.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2017, registered Apr 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.

Enrollment
21st of 44
42 · median 41
Started
2017
with 3 others
Phase 1
10 of 44
none open now
Registered
12th of 44
by date
Lead sponsor
4 of 44
Zai Lab (Shanghai) Co., Ltd.

Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 21st largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 1, and was the 12th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing niraparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

Niraparib is a potent and highly selective PARP-1/-2 inhibitor. The primary objective of this trial is to evaluate the pharmacokinetic (PK) properties of ZL-2306 (niraparib) and its metabolite M1 in patients from Mainland China with ovarian cancer, following a single and multiple oral administration of the study drug at the indicated dose (300mg, 200mg or 100mg), once a day.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • PARP inhibitor
  • BRCA mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Female, age ≥ 18 years.
  3. confirmed diagnosis of FIGO stage III or IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
  4. Has received no further than platinum-based chemotherapy, and has clinical complete response (CR) or partial response (PR) at least following 4 courses of the last platinum-based chemotherapy.
  5. 0-1.
  6. Has good organ function, including:
  7. Patient of , has a negative pregnancy test when enrolled and promises to use an adequate method of or abstain from activities that could result in pregnancy from enrolment to the end of study and during the 3 months after the last dose of the study treatment, or be of non-childbearing potential, can be enrolled in the study.
  8. Is able to adhere to the protocol.
  9. Has recovered from previous chemotherapy induced toxic side effects to ≤ grade 1 or basal level, apart from ≤ grade 2 CTCAE peripheral neuropathy or hair loss symptoms at steady state.

Exclusion criteria

Exclusion Criteria:

  1. Has a known to the active or inactive ingredients of ZL-2306 (niraparib) or compound which has similar chemical structure to ZL-2306 (niraparib).
  2. Has symptomatic uncontrolled brain or .
  3. Major surgery or chemotherapy within 3 weeks of starting the study or patient has not recovered from any effects of the surgery.
  4. Receive palliative radiotherapy encompassing > 20% of the bone marrow within 1 week of entering the study.
  5. Be diagnosed any invasive cancer other than ovarian cancer (apart from cured basal cell carcinoma and squamous cell carcinoma) within 2 years prior to study enrolment.
  6. Has a history or current diagnosis of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).
  7. Has other serious or uncontrolled disease
  8. Has any disease, treatment and laboratory abnormality that may interfere the study results and affect the fully attendance of study. Or the patient is considered to be not suitable for the study by the investigator. Cannot receive or red blood cell transfusion within 4 weeks of study drug administration.
  9. Pregnant, breastfeeding or expecting to conceive children during the study treatment period.
  10. (QTc) interval > 470 msec.
  11. Use proton pump inhibitors, antacids or histamine 2 (H2) blockers within 48hrs prior to the first drug administration for PK measurement.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    ZL-2306 (niraparib)

    Subjects will be randomised into 100mg, 200mg, 300mg dose group at the first day of the first cycle.

    Drug: ZL-2306 (niraparib)

Interventions

  • About 30 subjects will be enrolled to the study, and randomised into 300mg, 200mg and 100mg dose groups (about 10 subjects per group). All subjects will be randomised into indicated dose group (300mg, 200mg or 100mg) at the first day of the first cycle. A single administration of ZL-2306 (niraparib) will be given to the subjects at indicated dose.

06

What researchers measure

Primary outcomes

  1. Maximum plasma drug concentration (Cmax)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  2. Time to reach Cmax (Tmax)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  3. Terminal rate constant (λz)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  4. Elimination half-life (t1/2)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  5. Area under the plasma concentration-time curve from time zero to 24hrs (AUC (0-24))

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  6. Area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUC(0-t)) and from zero to infinity (AUC0-∞)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  7. Apparent total body clearance of the drug from plasma (CL/F)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  8. Apparent volume of distribution (Vd/f)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  9. Mean residence time (MRT)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  10. Degree of fluctuation (DF)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  11. Maximum plasma drug concentration at steady-state (Css max)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  12. Time to reach Css max (Tss max)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  13. Minimum plasma drug concentration at steady-state (Css min)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  14. Area under the plasma concentration-time curve from time zero to the end of drug administration (AUCss)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  15. Steady-state apparent total body clearance of drug from plasma (Clss/F)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  16. Accumulation ratio following multiple drug administration (RAC)

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

  17. The plasma drug concentration before drug administration

    Time frame: From pre-dose to day 1 of the 2nd cycle (each cycle is 28 days)

Secondary outcomes

  1. Number of participants with adverse events as assessed by CTCAE v4.0

    Time frame: From the signing of ICF till the end of this study (30 days after the last administration of the study drug or the date to close the clinical trial database, whichever is earlier)

07

Study locations

6 sites
  • Beijing Cancer Hospital
    Beijing, Beijing 100000, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510000, China
  • Haerbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Fudan University Shanghai Cnacer Center
    Shanghai, Shanghai 200000, China
  • The West China Second UniversityHospital of Sichuan University
    Chengdu, Sichuan 610000, China
08

References and documents

Publications

  • Zhang J, Zheng H, Gao Y, Lou G, Yin R, Ji D, Li W, Wang W, Xia B, Wang D, Hou J, Yan J, Hei Y, Zhang ZY, Milton A, Wu X. Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer. Oncologist. 2020 Jan;25(1):19-e10. doi: 10.1634/theoncologist.2019-0565. Epub 2019 Aug 22. PubMed 31439812 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in May 2018, 4 months.

Of 209 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 4 months is below that.

Counting every sponsor, half of 379 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2018
First posted
Jun 11, 2018
StartActual
Dec 19, 2017
Primary completionActual
May 3, 2018
CompletionActual
Jul 10, 2018
Last update
Jan 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03551171
Responsible party
Sponsor
First posted
Jun 11, 2018
Start date
Dec 19, 2017
Primary completion
May 3, 2018
Completion
Jul 10, 2018
Last update
Jan 24, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion